

# HER2 regulates cancer stem-like cell phenotype in *ALK* translocated NSCLC

TIIA HONKANEN<sup>1,2</sup>, EMMI WILENIUS<sup>1,2</sup>, PEPPI KOIVUNEN<sup>3-5</sup> and JUSSI P. KOIVUNEN<sup>1,2</sup>

<sup>1</sup>Department of Oncology and Radiotherapy, Oulu University Hospital, POB 20, 90029 OYS Oulu; <sup>2</sup>Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu; <sup>3</sup>Biocenter Oulu, POB 5000, 90014 University of Oulu; <sup>4</sup>Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu; <sup>5</sup>Oulu Center for Cell-Matrix Research, University of Oulu, Oulu, Finland

Received April 11, 2017; Accepted May 29, 2017

DOI: 10.3892/ijo.2017.4048

**Abstract.** We have previously shown that cancer stem-like cells (CSLCs) can mediate therapy resistance in *ALK* translocated lung cancers. HER2 has been linked to CSLCs in breast cancers and, therefore, we wanted to assess whether HER2 has a role in CSLCs in *ALK* translocated cancers. *ALK* translocated cell lines, H3122 and H2228, with variable sensitivity to *ALK* inhibition were used in the study. HER2 overexpression or knockdown was induced by retro- or lentiviral infections and cells were treated with pharmacological agents targeting HER2 and *ALK* signaling. Furthermore, tumorigenic properties of the cells were assessed *in vitro* using colony and sphere formation assays. In the *ALK* inhibitor sensitive H3122 cells, HER2 overexpression unaltered the primary response to *ALK* inhibition, but increased CSLC marker expression and enhanced colony and sphere formation and late AKT and ERK1/2 signaling recovery. In the *ALK* inhibitor semi-sensitive H2228 cells, *HER2* knockdown reduced basal expression of CSLC markers, modestly increased sensitivity to *ALK* inhibition in colony and sphere formation assays, and reduced late AKT and ERK1/2 signaling recovery. In addition, HER2 induced cross activation of other ErbB-members of which HER3 followed most closely the CSLC marker expression and neuregulin-1, a HER3 ligand, or pan-ErbB inhibitor afatinib,

were able to alter CSLC marker expression and colony formation. The present study suggests that HER2 has an important role in the regulation of the CSLC phenotype in *ALK* translocated lung cancers that is mainly orchestrated by HER2/HER3 heterodimers.

## Introduction

Approximately 7% of all non-small cell lung cancers (NSCLCs) contain chromosomal rearrangements of anaplastic lymphoma kinase (*ALK*), resulting in constitutively active *ALK*. *ALK* rearranged NSCLCs are often highly sensitive to *ALK* tyrosine kinase inhibitors (*ALK* TKIs) such as crizotinib. However, the *ALK* TKI-sensitive *ALK* rearranged NSCLCs will eventually develop targeted therapy resistance. Multiple different mechanisms for *ALK* TKI resistance have been reported, such as secondary mutations of *ALK*, or mutations in other somatic kinase domains, and activation of alternative signaling pathways through different receptor tyrosine kinases (RTKs), such as EGFR and HER2 (1-3).

Cancer stem-like cells (CSLCs) have often been linked to tumor initiation and therapy resistance. They have shown to be resistant both to the traditional chemo- and radiotherapies, and to targeted therapies, causing tumor relapses (4-8). Many signaling pathways have been described to be essential for CSLCs and potential cancer therapy targets have been discovered based on these pathways. Furthermore, some unspecific agents, like salinomycin and metformin, have been shown to target CSLCs (9,10). Currently, clinical utility of CSLC targeting agents is still unknown. We have previously shown that CSLCs can mediate therapy resistance in *ALK* translocated NSCLC cell lines (H2228 and H3122) and that targeting both *ALK* and CSLCs results in improved cell killing compared to either alone (6).

ErbB/HER family consists of four members: EGFR, HER2, HER3 and HER4. When activated, ErbB/HER family members form either homo- or heterodimers, which can signal downstream to the PI3K-AKT or Ras-Raf-MEK pathways. EGFR and HER2 receptors are commonly altered in some cancers, like breast cancers and NSCLCs, and act as cancer driving oncogenes. HER3 and HER4 have also shown to be expressed in cancers, but their activating genetic alterations

---

**Correspondence to:** Dr Jussi P. Koivunen, Department of Oncology and Radiotherapy, Oulu University Hospital, POB 20, 90029 OYS, Finland  
E-mail: jussi.koivunen@ppshp.fi

**Abbreviations:** ALDH1, aldehyde dehydrogenase 1; *ALK*, anaplastic lymphoma kinase; CSLC, cancer stem-like cell; EGF, epidermal growth factor; ErbB, erythroblastic leukemia viral oncogene homolog; HER, human epidermal growth factor receptor; NRG1, neuregulin-1; NSCLC, non-small cell lung cancer; RTK, receptor tyrosine kinase; TKI, tyrosine kinase inhibitor

**Key words:** targeted cancer therapy, resistance, cancer stem-like cells, *ALK*, HER2

are uncommon. Co-expression of different HER receptors have been linked to a worse outcome/poor prognosis, especially EGFR and HER2 co-expression (11-14). Furthermore, HER family receptors, especially HER2, have been linked to CSLCs. Overexpression of HER2 has been shown to increase not only the amount of CSLC population in series of breast carcinoma cell lines, but also the tumorigenicity in NOD/SCID mice (15-18). Since numerous clinically active HER2 targeting agents, such as trastuzumab, pertuzumab and lapatinib, are approved, characterization of CSLC dependency on HER2 could lead to rapid clinical testing of the agents in the context of CSLC targeting.

In the present study, we investigate the role of HER2 for CSLCs in ALK translocated NSCLC cell lines. The results suggest that HER2 plays an important role in the CSLC phenotype.

## Materials and methods

**Cell lines, inhibitors and growth factors.** The cell lines used in the present study included ALK translocated NSCLC lines H3122 and H2228, and their counterparts modified to overexpress GFP or HER2 (H3122) or to knock down GFP or HER2 (H2228). The original cell lines were a kind gift from Dr Pasi Jänne (Dana-Farber Cancer Institute, Boston, MA, USA). The cell lines were grown in RPMI-1640 medium (Thermo Fisher Scientific, Waltham, MA, USA and Sigma-Aldrich, St. Louis, MO, USA) with 10% fetal bovine serum (FBS) and 100 IU/ml penicillin and streptomycin (Thermo Fisher Scientific). Cells were incubated at 37°C with 5% CO<sub>2</sub> in the atmosphere. Following inhibitors were used: TAE684 (a gift from Dr Nathanael Gray, Dana-Farber Cancer Institute), crizotinib, afatinib (LC Laboratories, Woburn, MA, USA) and lapatinib (Alexis Biochemicals, Lausen, Switzerland). Neuregulin-1 (NRG1) and epidermal growth factor (EGF) were also used (Thermo Fisher Scientific). Inhibitors were diluted in dimethyl sulfoxide (DMSO) and stored at -20°C while growth factors were diluted in sterile, distilled water and stored at -80°C.

**Lentiviral knockdown and retroviral overexpression.** Lentiviral and retroviral vectors were used to achieve overexpression or knockdown of GFP and HER2 in the H3122 and H2228 cell lines. HER2 shRNA vector was purchased from Sigma-Aldrich. GFP shRNA vector and both retroviral vectors used for overexpression were kind gifts from Dr Pasi Jänne (Dana-Farber Cancer Institute). 293T cells were transfected with lenti-/retroviral expression vectors and packaging plasmids using FuGENE 6 reagent (Roche Diagnostics, Mannheim, Germany). Lentiviral supernatants were collected 24 h and retroviral supernatants 48 h after transfection. Both supernatants were filtered through 0.45 µm filter and applied to the target cells in the presence of Polybrene (Sigma-Aldrich). After 48 h of infections, the target cells were selected with puromycin (Sigma-Aldrich) for 72-96 h.

**Western blot analysis.** The cells were plated on 6-well plates, allowed to attach for 1-2 days and treated with desired drugs for 5 h or 5 days, after which they were lysed with NP-40 lysis buffer (20 mM Tris-HCl pH 8.0, 137 mM NaCl, 10% glyc-

erol, 2 mM EDTA, 1 mM sodium orthovanadate, 1% igepal CA-630, 10 µg/ml aprotinin and 10 µg/ml leupeptin). Protein concentrations were measured with Bio-Rad Protein assay (Bio-Rad Laboratories, Hercules, CA, USA). After equalizing the concentrations Laemmli buffer was added, the samples were boiled and stored at -80°C.

Equal amounts of protein samples were separated on SDS-PAGE and proteins were transferred to PVDF membranes, after which the membranes were blocked with 5% BSA (1x PBS, 0.1% Tween-20, 0.005% sodium azide) and incubated in primary antibodies overnight at 4°C. Horseradish peroxidase (HRP)-linked secondary antibody was used, the membranes were developed using chemiluminescence and exposed to radiographic film. The quantification of western blot images was performed with ImageJ software, measuring the intensities (pixel percentages) for each sample in the same membrane with equal, manually selected area.

Following antibodies were used: ALDH1 (BD Transduction Laboratories, Franklin Lakes, NJ, USA), Akt, phospho-Akt (S473), CD44, cleaved PARP, EGFR, phospho-EGFR (Y1068), ERK1/2, phospho-ERK1/2 (T202/Y204), HER2, phospho-HER2 (Y1221/1222), HER3, phospho-HER3 (Y1289), HER4, phospho-HER4 (Y1284), anti-mouse/rabbit HRP-linked secondary antibody (Cell Signaling Technology, Danvers, MA, USA) and β-actin (Sigma-Aldrich). All antibodies were diluted in 5% BSA, and used at 1:1,000, 1:20,000 (β-actin), or 1:3,000 (secondary antibodies) dilutions.

**Colony formation assay.** Cells (600-1,000) were plated on 24-well plates with duplicates, allowed to attach for 1-2 days and treated with drugs. After 7 days, the drugs were withdrawn and the cells were allowed to recover and form colonies for several weeks. After clear differences were observed in the growth of colonies, the cells were fixed with ice-cold methanol and dyed with crystal violet stain.

**Tumor sphere formation assay.** The cells were treated with or without ALK TKI for 5 days, after which the cells were plated on 6-well ultra-low attachment plates (Corning Inc., Corning, NY, USA). A total of 5,000 (H3122) or 7,000 (H2228) cells were seeded on each well with or without further ALK TKI treatment. The cells were cultured in Dulbecco's modified Eagle's medium (DMEM)/F-12 media with 20 ng/ml EGF, 20 ng/ml bFGF, 1% B27 supplement and 100 IU/ml penicillin and streptomycin (Thermo Fisher Scientific). The spheres were allowed to grow for 15 days, after which images were taken and the sphere numbers were counted. Magnification (x10) in phase contrast microscope was used when imaging the largest spheres from each well.

## Results

**HER2 alters expression of CSLC markers.** We initially accessed whether two EML4-ALK translocated NSCLC cell lines, H3122 and H2228, basally expressed HER2. In the H3122 cells, which are very sensitive to ALK inhibition, basal HER2 expression was undetectable (Fig. 1A). Conversely, the H2228 cells, modestly sensitive to ALK inhibition, showed basal expression of HER2 (Fig. 1A). The overexpression of HER2 with a retroviral expression vector was successful in




Figure 1. Western blot analysis for cancer stem-like cell markers, ALDH1 and CD44, in *ALK* translocated, GFP or *HER2* altered NSCLC lines (H3122, H2228). (A) Validation of *HER2* overexpression and knockdown. (B) ALDH1 expression in H3122 with retrovirally induced GFP or *HER2* overexpression untreated or treated for 5 days with ALK TKI. (C) ALDH1 and CD44 expression in H2228 cells with lentiviral *GFP* or *HER2* knock-down untreated or treated for 5 days with ALK TKI. The percentages are defined as pixel intensities within equally sized areas for each membrane.

H3122 cells with a marked increase in the expression level of the protein (Fig. 1A). Furthermore, knockdown of *HER2* with lentiviral shRNA vector induced a complete or near complete downregulation of the protein expression in the H2228 line (Fig. 1A).

We next accessed whether overexpression or knockdown of *HER2* resulted in changes to CSLCs. We have previously shown that CSLCs, indicated by specific markers ALDH1 (H3122) and CD44/ALDH1 (H2228), can mediate the ALK TKI resistance (6). As in our previous studies, ALDH1 expression increased in the H3122 cells in response to ALK inhibition (Fig. 1B), suggesting CSLC mediated resistance. Overexpression of *HER2* in H3122 did not change the basal ALDH1 expression, but when the cells were challenged with ALK TKI, this resulted in more pronounced expression of CSLC marker (Fig. 1B). Knockdown of *HER2* in the H2228 cells resulted in basal downregulation of ALDH1, but unaltered expression of CD44 (Fig. 1C), a marker previously linked most strongly to CSLCs in this cell line (6). Moreover, marked CD44 downregulation was only seen in *HER2* knock-down H2228 cells when they were challenged with ALK TKI (Fig. 1C).

**Role of *HER2* in cytotoxic response to ALK TKI.** The *HER2* overexpressing H3122 cells or the *HER2* knockdown H2228 cells were next exposed to ALK TKIs to see whether their




Figure 2. Colony formation and apoptosis of *ALK* translocated cell lines. (A) Colony formation assay in GFP or *HER2* altered H3122 and H2228 cells untreated or treated with ALK, *HER2* (lapatinib), pan-*HER* (afatinib) TKIs or their combinations for 7 days, after which the colonies were allowed to regrow without drugs. (B) Western blot analysis for cleaved PARP (cPARP, apoptosis) in GFP or *HER2* altered H3122 and H2228 cell lines treated with ALK or *HER2* TKIs or their combination.

colony formation and apoptotic responses to ALK inhibition was altered. In the colony formation assay, major cytotoxicity response to ALK inhibition remained unaffected by the *HER2* alterations (Fig. 2A). However, the ALK inhibitor treatment in the H3122 cells with *HER2* overexpression resulted in increased number of surviving colonies compared to controls (Fig. 2A). Analogously, the ALK inhibitor treated H2228 cells with *HER2* knockdown had a modestly decreased number of surviving colonies (Fig. 2A). When the H3122 and H2228 cells were treated with a single *HER2* specific inhibitor lapatinib, no change in cell survival was seen (Fig. 2A). The pan-*HER* (EGFR, *HER2* and *HER4*) inhibitor afatinib, however, decreased the number of surviving colonies modestly in both tested cell lines (Fig. 2A). There was no difference in single-agent afatinib responses between the *HER2* altered and control cells (Fig. 2A). Combination of ALK TKI with either lapatinib or afatinib resulted in total inhibition of colony formation in *HER2* overexpressing H3122 cells (Fig. 2A). In H2228 cells, combined inhibition lead to a more pronounced colony inhibition in the *HER2* knockdown cells, afatinib being more potent than lapatinib in this setting (Fig. 2A).

Next, we wanted to assess, whether *HER2* alteration would affect apoptotic response in the cell lines using western blot analysis for the apoptotic marker cleaved PARP. In H3122 control cells, cleaved PARP was detected in cells treated with ALK TKI and its combination with afatinib (Fig. 2B). In the H3122 cells overexpressing *HER2*, cleaved PARP was only detected following a combined treatment




Figure 3. Sphere formation assay. (A) Sphere formation assay in GFP or HER2 altered H3122 and H2228 cell lines untreated or treated with ALK TKI for 5 or 15 days. Number of spheres are shown in the column chart. (B) Representative phase contrast images of the spheres with x10 magnification.




Figure 4. Western blot analysis for receptor downstream signaling proteins AKT and ERK1/2 in GFP or HER2 altered H3122 and H2228 cell lines after 5-h or 5-day treatments with ALK TKIs.

seen in control cells, and the *HER2* knockdown did not have an effect on this (Fig. 2B).

**Role of *HER2* in sphere formation.** Sphere formation assay is one of the most used assay to identify CSLCs *in vitro* and therefore, we assessed whether *HER2* alteration would modify the sphere formation of the *ALK* translocated H3122 or H2228 cells. We exposed the control and *HER2* altered cells to ALK TKI *in vitro* for 5 or 15 days in stem cell enriching sphere formation environment with special media and low-attaching culture plates. In untreated cells, *HER2* had no effect in the sphere formation capacity (Fig. 3). In H2228 cells treated with ALK TKI, *HER2* knockdown was able to inhibit sphere formation at 5 days compared to control cells while no surviving spheres were seen at 15 days (Fig. 3). H3122 cells with *HER2* overexpression were able to form spheres in the presence of ALK TKI while this capacity was markedly reduced in control cells treated with ALK TKI for 5 or 15 days (Fig. 3).

*HER2* is essential to *AKT* and *ERK1/2* downstream signaling in long-term exposure to ALK TKI. PI3K and MAPK pathways are one of the most important downstream signaling pathways controlled by RTKs, such as ALK and *HER2* (3,19,20). To

with ALK TKI and afatinib (Fig. 2B). In H2228 cells, analogously to previous study (3), no cleaved PARP signal was




Figure 5. Effects of HER2 alterations and neuregulin-1 (NRG1) on ErbB-family signaling. Western blot analysis for ErbB-family activation, downstream signaling, and PARP cleavage (cPARP, apoptosis) in (A) GFP/HER2 overexpressed cell line H3122, and (B) *GFP/HER2* knockdown cell line H2228 untreated or treated with ALK TKIs and NRG1 for 5 days. (C) Colony formation assay of GFP/HER2 altered H3122 and H2228 cell lines treated with ALK TKI or NRG1 or their combination for 7 days, after which the colonies were allowed to regrow. (D) Expression of cancer stem-like cell marker ALDH1 after a 5-day treatment with ALK TKI, afatinib, NRG1, epidermal growth factor (EGF) or their combinations.

examine the effects of HER2 overexpression and knockdown to initial and long-term downstream signaling, phosphorylation of AKT and ERK1/2 proteins was investigated at 5 h and 5 days after initiation of ALK inhibition. The overexpression of HER2 in H3122 cells did not change the AKT or ERK1/2 responses to short-term (5 h) ALK TKI treatment (Fig. 4). Long-term (5 days) treatment of HER2 overexpressing H3122 cells with ALK TKIs, however, resulted in reformed downstream RTK signaling with major upregulation of both phosphorylated AKT and ERK1/2 (Fig. 4). In H2228 cells, initial response (5 h) to ALK TKIs was similar in the *HER2* knockdown cells (Fig. 4). Similarly to H3122 cells, HER2 altered H2228 cells showed different long-term (5 days) ALK TKI responses in downstream signaling (Fig. 4). In control H2228 cells, initial downregulation of AKT and ERK1/2

phosphorylation was completely recovered at 5 days while the downregulation remained in the *HER2* knockdown cells (Fig. 4).

*HER2 orchestrates ErbB-family signaling.* Next, we wanted to study whether *HER2* overexpression or knockdown had any effects on other ErbB/HER-family members and their activation, since HER2 forms not only homodimers but also heterodimers with all the other members of the protein family (21). In the H3122 control cells, only EGFR and HER3 were expressed without evidence of their activation by absence of phosphorylated protein counterparts (Fig. 5A). HER2 overexpression increased both expression and phosphorylation of EGFR and HER4 proteins, and phosphorylation of HER3 (Fig. 5A). In H2228 cells, only EGFR and HER2 were basally

expressed and no phosphorylation of the proteins was detected (Fig. 5B). Knockdown of *HER2* resulted in downregulated expression of HER3 (Fig. 5B).

Since *HER2* alteration resulted in changes to *HER3* and/or *HER4* in both cell lines, we assessed whether neuregulin-1 (*NRG1*), only known joint *HER3* and *HER4* ligand and linked to tumor initiating cells (22), would modify behavior of the cells. In colony formation assay, *NRG1* itself did not alter the number of colonies (Fig. 5C). As previously described, H3122 cells with *HER2* overexpression showed increased number of surviving colonies in ALK TKI treated cells compared controls (Fig. 2A). When H3122 cells were treated with *NRG1* in combination with ALK TKI, there was marked difference between the *HER2* overexpressing and control cells (Fig. 5C). *HER2* overexpressing cells showed a marked increase in the number of surviving colonies while the control cells showed only a minor increase (Fig. 5C). In H2228 cells, *HER2* knockdown did not affect the *NRG1* response (Fig. 5C).

The cells were further analyzed for cell signaling, apoptotic response and/or CSLC marker expression after the *NRG1* exposure. Especially in the H3122 line, *NRG1* treatment altered all the analyzed responses (Fig. 5A). In H3122 cells, the most prominent effect of *NRG1* was seen in *HER3* phosphorylation (Fig. 5A). In control cells, *NRG1* was able to induce *HER3* phosphorylation in the ALK TKI treated cells, which was accompanied by upregulation of phosphorylated AKT, inhibition of apoptosis (cleaved PARP) and increased expression of CSLC markers (Fig. 5A). In *HER2* overexpressing cells, *HER3* phosphorylation was already detectable in cells treated with *NRG1* alone and the most prominent expression was seen when it was combined to ALK TKI (Fig. 5A). Furthermore, *NRG1* and ALK TKI combination induced the strongest expression of CSLC markers (Fig. 5A). In H2228 cells, *NRG1* induced increase in *ALDH1* expression, most notably in control cells (Fig. 5B). Only minor changes were seen in the *CD44* expression, some rescue of ALK TKI induced downregulation of the marker detected in the *HER2* knockdown cells by *NRG1* (Fig. 5B). We also assessed the effects of EGF, another *HER* ligand, mainly activating *EGFR*, on CSLC marker expression in the H3122 cells with *HER2* alterations. However, EGF was unable to stimulate CSLC marker expression alone or in combination with ALK TKI (Fig. 5D).

## Discussion

CSLCs have been linked to chemo-, radio- and targeted therapy resistance (4,7,8). Molecular mechanisms behind CSLC phenotype are largely unknown, but some signaling pathways such as *wnt/β-catenin*, *TGF-β* and *HER2* pathways have been linked to it (23-25). Understanding molecular mechanisms of CSLCs would enable more efficient cancer treatment with combinatory approaches. Early phase clinical trials are testing some agents suggested to target CSLCs but no clear evidence of their effectiveness have been presented.

*ALK* translocated NSCLC represents a subgroup of disease in which patients are highly sensitive to ALK inhibitors, such as crizotinib. As with other targeted agents, acquired resistance to ALK inhibitors develops ~10-12 months after therapy initiation. Molecular mechanisms of ALK inhibitor resistance

includes secondary mutations in tyrosine kinase domain of ALK, activation of by-pass signaling mechanisms and CSLC phenotype (3,6,26). Many previous reports have linked the *ErbB*-pathway activation mediated by-pass signaling mechanisms to ALK TKI resistance (3,6,27-29). The present study assessed whether *ErbB*-signaling affects the CSLC acquired in *ALK* translocated NSCLC models. We used two model cell lines, which we have previously shown to be either sensitive or modestly sensitive to ALK inhibition and CSLC phenotype to be related to therapy resistance.

Of the *ErbB*-pathways, *HER2* has been linked most strongly to CSLC phenotype (17). *HER2* targeting antibody trastuzumab is approved only for the treatment of *HER2* amplified breast cancer. However, reassessment of studies of *HER2* amplification have identified that some patients without amplification can benefit from adjuvant trastuzumab therapy (30,31). It has been speculated that benefit without *HER2* amplification could relate to CSLC targeting activity of trastuzumab. Our results showed that *HER2* expression correlated with CSLC markers and sphere formation in *ALK* translocated models. More precisely, *HER2* overexpression resulted more pronounced stem-like cell marker in response to ALK TKI while knockdown of the gene inhibited TKI induced stem-like cell phenotype. These results further highlight the importance of *HER2* in CSLC. Our results showed not only the correlation between stem-like cell marker expression and *HER2* but also pointed towards functionality of *HER2* to stem-like cells assessed by colony or sphere formation. Genomic or pharmacologic alteration of *HER2* modifies colony and sphere formation ability of *ALK* translocated models, *HER2* correlating with increased capability. Since numerous agents targeting *ErbB*-signaling components are available in clinic, it would be interesting to test them in context of CSLC targeting as a combinatory approach.

Our experimentation showed that initial cytotoxic response or downstream receptor signaling (occurring in hours) to ALK TKIs was not changed by *HER2* alterations. Notably, there was a marked change in the number of surviving colonies and downstream receptor signaling after long-term exposure (days) to ALK TKIs according *HER2* status. More precisely, *HER2* overexpression was able to markedly reactivate the AKT and ERK signaling after long-term exposure to ALK TKIs compared to controls. Analogously, *HER2* knockdown resulted in less recovery of AKT and ERK signaling after long ALK TKI treatment. More pronounced effects of *HER2* alterations were seen in AKT rather than in ERK signaling. Many previous studies have linked AKT-mTOR signaling to CSLC phenotype and targeting this pathway has been shown to inhibit CSLCs (24,32-34). In *ALK* translocated cancers, AKT and ERK signaling is mainly driven by ALK and signaling recovery after long exposures to ALK inhibition is generally unknown. The present study suggests the importance of *HER2* in this signaling recovery.

*ErbB*-family members can form homo- or heterodimers, which signal downstream of AKT and ERK with variable preference (19,21). In *HER2* amplified breast cancer, *HER2-HER3* heterodimer is thought to be the most important signaling component, which preferentially signals through AKT-mTOR (35,36). *HER3/HER4* ligand *NRG1* mainly promotes AKT-mTOR signaling and interestingly, has

previously been linked to tumor initiating cells/CSLCs (22). This study suggests that HER2 orchestrates all other ErbB-family members. Expression of CSLC marker ALDH1 followed most closely HER3. NRG1 and long ALK TKI treatment promoted CSLC marker expression and HER3, which was accompanied by increased colony formation. This suggests that HER2/HER3 heterodimer could play an important role in CSLCs of ALK translocated lung cancers.

This study investigated the role of HER2 in CSLCs using ALK translocated lung cancer as a model. The results of the study suggest that HER2 has an important role in CSLC phenotype *in vitro* mainly orchestrated by HER2/HER3 heterodimers.

### Acknowledgements

The present study was supported by the Cancer Foundation of Finland.

### References

1. Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, *et al*: Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. *Clin Cancer Res* 18: 1472-1482, 2012.
2. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, *et al*: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature* 448: 561-566, 2007.
3. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, *et al*: EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. *Clin Cancer Res* 14: 4275-4283, 2008.
4. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. *Nature* 444: 756-760, 2006.
5. De Cola A, Volpe S, Budani MC, Ferracin M, Lattanzio R, Turdo A, D'Agostino D, Capone E, Stassi G, Todaro M, *et al*: miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance. *Cell Death Dis* 6: e1823, 2015.
6. Jokinen E, Laurila N, Koivunen P and Koivunen JP: Combining targeted drugs to overcome and prevent resistance of solid cancers with some stem-like cell features. *Oncotarget* 5: 9295-9307, 2014.
7. Shien K, Toyooka S, Yamamoto H, Soh J, Jida M, Thu KL, Hashida S, Maki Y, Ichihara E, Asano H, *et al*: Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. *Cancer Res* 73: 3051-3061, 2013.
8. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, *et al*: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. *J Natl Cancer Inst* 100: 672-679, 2008.
9. Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, Yang SX and Ivy SP: Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: Clinical update. *Nat Rev Clin Oncol* 12: 445-464, 2015.
10. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA and Lander ES: Identification of selective inhibitors of cancer stem cells by high-throughput screening. *Cell* 138: 645-659, 2009.
11. Abd El-Rehim DM, Pinder SE, Paish CE, Bell JA, Rampaul RS, Blamey RW, Robertson JF, Nicholson RI and Ellis IO: Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. *Br J Cancer* 91: 1532-1542, 2004.
12. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, *et al*: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 350: 2129-2139, 2004.
13. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, *et al*: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med* 344: 783-792, 2001.
14. Suo Z, Risberg B, Kallson MG, Willman K, Tierens A, Skovlund E and Nesland JM: EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. *J Pathol* 196: 17-25, 2002.
15. Ithimakin S, Day KC, Malik F, Zen Q, Dawsey SJ, Bersano-Begey TF, Quraishi AA, Ignatoski KW, Daignault S, Davis A, *et al*: HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: Implications for efficacy of adjuvant trastuzumab. *Cancer Res* 73: 1635-1646, 2013.
16. Clark PA, Iida M, Treisman DM, Kalluri H, Ezhilan S, Zorniak M, Wheeler DL and Kuo JS: Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition. *Neoplasia* 14: 420-428, 2012.
17. Korkaya H, Paulson A, Iovino F and Wicha MS: HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. *Oncogene* 27: 6120-6130, 2008.
18. Sette G, Salvati V, Mottolese M, Visca P, Gallo E, Fecchi K, Pillozzi E, Duranti E, Policicchio E, Tartaglia M, *et al*: Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer. *Cell Death Dis* 6: e1850, 2015.
19. Schulze WX, Deng L and Mann M: Phosphotyrosine interactome of the ErbB-receptor kinase family. *Mol Syst Biol* 1: 0008, 2005.
20. Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandraratna S, Markman B, Rodriguez O, Guzman M, Rodriguez S, *et al*: PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. *Oncogene* 30: 2547-2557, 2011.
21. Hynes NE and Lane HA: ERBB receptors and cancer: The complexity of targeted inhibitors. *Nat Rev Cancer* 5: 341-354, 2005.
22. Hegde GV, de la Cruz CC, Chiu C, Alag N, Schaefer G, Crocker L, Ross S, Goldenberg D, Merchant M, Tien J, *et al*: Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer. *Sci Transl Med* 5: 171ra18, 2013.
23. Malanchi I, Peinado H, Kassen D, Hussenet T, Metzger D, Chambon P, Huber M, Hohl D, Cano A, Birchmeier W, *et al*: Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. *Nature* 452: 650-653, 2008.
24. Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutcher J, Clouthier SG and Wicha MS: Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. *PLoS Biol* 7: e1000121, 2009.
25. Anido J, Sáez-Borderías A, González-Juncá A, Rodón L, Folch G, Carmona MA, Prieto-Sánchez RM, Barba I, Martínez-Sáez E, Prudkin L, *et al*: TGF- $\beta$  receptor inhibitors target the CD44<sup>high</sup>/Id1<sup>high</sup> glioma-initiating cell population in human glioblastoma. *Cancer Cell* 18: 655-668, 2010.
26. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, *et al*: Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. *Sci Transl Med* 4: 120ra17, 2012.
27. Isozaki H, Ichihara E, Takigawa N, Ohashi K, Ochi N, Yasugi M, Ninomiya T, Yamane H, Hotta K, Sakai K, *et al*: Non-small cell lung cancer cells acquire resistance to the ALK inhibitor alectinib by activating alternative receptor tyrosine kinases. *Cancer Res* 76: 1506-1516, 2016.
28. Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, Lathan C, Marcoux JP, Du J, Okuda K, *et al*: A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. *Cancer Res* 71: 6051-6060, 2011.
29. Tanizaki J, Okamoto I, Okabe T, Sakai K, Tanaka K, Hayashi H, Kaneda H, Takezawa K, Kuwata K, Yamaguchi H, *et al*: Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. *Clin Cancer Res* 18: 6219-6226, 2012.
30. Paik S, Kim C and Wolmark N: HER2 status and benefit from adjuvant trastuzumab in breast cancer. *N Engl J Med* 358: 1409-1411, 2008.

31. Perez EA, Reinholz MM, Hillman DW, Tenner KS, Schroeder MJ, Davidson NE, Martino S, Sledge GW, Harris LN, Gralow JR, *et al*: HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. *J Clin Oncol* 28: 4307-4315, 2010.
32. Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, Apuzzo T, Sperduti I, Volpe S, Cocorullo G, *et al*: CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. *Cell Stem Cell* 14: 342-356, 2014.
33. Xia P and Xu XY: PI3K/Akt/mTOR signaling pathway in cancer stem cells: From basic research to clinical application. *Am J Cancer Res* 5: 1602-1609, 2015.
34. Zhu Y, Zhang X, Liu Y, Zhang S, Liu J, Ma Y and Zhang J: Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo. *Tumour Biol* 33: 1349-1362, 2012.
35. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF III and Hynes NE: The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. *Proc Natl Acad Sci USA* 100: 8933-8938, 2003.
36. Vaught DB, Stanford JC, Young C, Hicks DJ, Wheeler F, Rinehart C, Sánchez V, Koland J, Muller WJ, Arteaga CL, *et al*: HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. *Cancer Res* 72: 2672-2682, 2012.